Literature DB >> 24585779

Hyperhomocysteinemia attenuates angiogenesis through reduction of HIF-1α and PGC-1α levels in muscle fibers during hindlimb ischemia.

Sudhakar Veeranki1, Srikanth Givvimani, Sathnur Pushpakumar, Suresh C Tyagi.   

Abstract

Hyperhomocysteinemia (HHcy) is associated with elderly frailty, skeletal muscle injury and malfunction, reduced vascular integrity and function, and mortality. Although HHcy has been implicated in the impairment of angiogenesis after hindlimb ischemia in murine models, the underlying mechanisms are still unclear. We hypothesized that HHcy compromises skeletal muscle perfusion, collateral formation, and arteriogenesis by diminishing postischemic vasculogenic responses in muscle fibers. To test this hypothesis, we created femoral artery ligation in wild-type and heterozygous cystathionine β-synthase (CBS(+/-)) mice (a model for HHcy) and assessed tissue perfusion, collateral vessel formation, and skeletal muscle function using laser-Doppler perfusion imaging, barium angiography, and fatigue tests. In addition, we assessed postischemic levels of VEGF and levels of its muscle-specific regulators: hypoxia-inducible factor (HIF)-1α and peroxisome proliferator-activated receptor-γ coactivator (PGC)-1α. The observations indicated dysregulation of VEGF, HIF-1α, and PGC-1α levels in ischemic skeletal muscles of CBS(+/-) mice. Concomitant with the reduced ischemic angiogenic responses, we also observed diminished leptin expression and attenuated Akt signaling in ischemic muscle fibers of CBS(+/-) mice. Moreover, there was enhanced atrogene, ubiquitin ligases that conjugate proteins for degradation during muscle atrophy, transcription, and reduced muscle function after ischemia in CBS(+/-) mice. These results suggest that HHcy adversely affects muscle-specific ischemic responses and contributes to muscle frailty.

Entities:  

Keywords:  Akt; CD31; angiogenesis; atrogin-1; hyperhomocysteinemia; hypoxia-inducible factor; ischemia; leptin; muscle ring finger-1; peroxisome proliferator-activated receptor-γ coactivator-1α; skeletal muscle; vascular endothelial growth factor

Mesh:

Substances:

Year:  2014        PMID: 24585779      PMCID: PMC3989752          DOI: 10.1152/ajpheart.00003.2014

Source DB:  PubMed          Journal:  Am J Physiol Heart Circ Physiol        ISSN: 0363-6135            Impact factor:   4.733


  55 in total

1.  HIF-1 is expressed in normoxic tissue and displays an organ-specific regulation under systemic hypoxia.

Authors:  D M Stroka; T Burkhardt; I Desbaillets; R H Wenger; D A Neil; C Bauer; M Gassmann; D Candinas
Journal:  FASEB J       Date:  2001-11       Impact factor: 5.191

2.  Hypoxia induces PGC-1α expression and mitochondrial biogenesis in the myocardium of TOF patients.

Authors:  Lingyun Zhu; Qiang Wang; Lin Zhang; Zhixiang Fang; Fang Zhao; Zhiyuan Lv; Zuguang Gu; Junfeng Zhang; Jin Wang; Ke Zen; Yang Xiang; Dongjin Wang; Chen-Yu Zhang
Journal:  Cell Res       Date:  2010-04-06       Impact factor: 25.617

3.  Stabilized HIF-1alpha is superior to VEGF for angiogenesis in skeletal muscle via adeno-associated virus gene transfer.

Authors:  Katri Pajusola; Jaana Künnapuu; Sanna Vuorikoski; Jarkko Soronen; Helder André; Teresa Pereira; Petra Korpisalo; Seppo Ylä-Herttuala; Lorenz Poellinger; Kari Alitalo
Journal:  FASEB J       Date:  2005-06-15       Impact factor: 5.191

4.  Homocysteine levels and decline in physical function: MacArthur Studies of Successful Aging.

Authors:  Deborah M Kado; Alexander Bucur; Jacob Selhub; John W Rowe; Teresa Seeman
Journal:  Am J Med       Date:  2002-11       Impact factor: 4.965

5.  Increased endogenous H2S generation by CBS, CSE, and 3MST gene therapy improves ex vivo renovascular relaxation in hyperhomocysteinemia.

Authors:  Utpal Sen; Pushpakumar B Sathnur; Sourav Kundu; Srikanth Givvimani; Denise M Coley; Paras K Mishra; Natia Qipshidze; Neetu Tyagi; Naira Metreveli; Suresh C Tyagi
Journal:  Am J Physiol Cell Physiol       Date:  2012-04-18       Impact factor: 4.249

6.  Human VEGF gene expression in skeletal muscle: effect of acute normoxic and hypoxic exercise.

Authors:  R S Richardson; H Wagner; S R Mudaliar; R Henry; E A Noyszewski; P D Wagner
Journal:  Am J Physiol       Date:  1999-12

7.  Mice deficient in cystathionine beta-synthase: animal models for mild and severe homocyst(e)inemia.

Authors:  M Watanabe; J Osada; Y Aratani; K Kluckman; R Reddick; M R Malinow; N Maeda
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

8.  Gene transfer of stromal cell-derived factor-1alpha enhances ischemic vasculogenesis and angiogenesis via vascular endothelial growth factor/endothelial nitric oxide synthase-related pathway: next-generation chemokine therapy for therapeutic neovascularization.

Authors:  Ken-ichi Hiasa; Minako Ishibashi; Kisho Ohtani; Shujiro Inoue; Qingwei Zhao; Shiro Kitamoto; Masataka Sata; Toshihiro Ichiki; Akira Takeshita; Kensuke Egashira
Journal:  Circulation       Date:  2004-05-17       Impact factor: 29.690

9.  PATHOLOGICAL FINDINGS IN HOMOCYSTINURIA.

Authors:  J B GIBSON; N A CARSON; D W NEILL
Journal:  J Clin Pathol       Date:  1964-07       Impact factor: 3.411

10.  Potential role of leptin in angiogenesis: leptin induces endothelial cell proliferation and expression of matrix metalloproteinases in vivo and in vitro.

Authors:  H Y Park; H M Kwon; H J Lim; B K Hong; J Y Lee; B E Park; Y Jang; S Y Cho; H S Kim
Journal:  Exp Mol Med       Date:  2001-06-30       Impact factor: 8.718

View more
  13 in total

1.  Cardiac myocyte p38α kinase regulates angiogenesis via myocyte-endothelial cell cross-talk during stress-induced remodeling in the heart.

Authors:  Beth A Rose; Tomohiro Yokota; Vishnu Chintalgattu; Shuxun Ren; Luisa Iruela-Arispe; Aarif Y Khakoo; Susumu Minamisawa; Yibin Wang
Journal:  J Biol Chem       Date:  2017-06-21       Impact factor: 5.157

2.  Role of mitochondrial fission and fusion in cardiomyocyte contractility.

Authors:  S Givvimani; S B Pushpakumar; N Metreveli; S Veeranki; S Kundu; S C Tyagi
Journal:  Int J Cardiol       Date:  2015-03-25       Impact factor: 4.164

3.  Hydrogen sulfide alleviates hyperhomocysteinemia-mediated skeletal muscle atrophy via mitigation of oxidative and endoplasmic reticulum stress injury.

Authors:  Avisek Majumder; Mahavir Singh; Jyotirmaya Behera; Nicholas T Theilen; Akash K George; Neetu Tyagi; Naira Metreveli; Suresh C Tyagi
Journal:  Am J Physiol Cell Physiol       Date:  2018-08-15       Impact factor: 4.249

Review 4.  Nitric Oxide and Hydrogen Sulfide Regulation of Ischemic Vascular Growth and Remodeling.

Authors:  Saranya Rajendran; Xinggui Shen; John Glawe; Gopi K Kolluru; Christopher G Kevil
Journal:  Compr Physiol       Date:  2019-06-12       Impact factor: 9.090

5.  Nitrite Prevents Right Ventricular Failure and Remodeling Induced by Pulmonary Artery Banding.

Authors:  Jian Hu; Maryam Sharifi-Sanjani; Stevan P Tofovic
Journal:  J Cardiovasc Pharmacol       Date:  2017-02       Impact factor: 3.105

6.  Hyperhomocysteinemia inhibits satellite cell regenerative capacity through p38 alpha/beta MAPK signaling.

Authors:  Sudhakar Veeranki; David Lominadze; Suresh C Tyagi
Journal:  Am J Physiol Heart Circ Physiol       Date:  2015-05-15       Impact factor: 4.733

7.  Hyperhomocysteinemia associated skeletal muscle weakness involves mitochondrial dysfunction and epigenetic modifications.

Authors:  Sudhakar Veeranki; Lee J Winchester; Suresh C Tyagi
Journal:  Biochim Biophys Acta       Date:  2015-01-20

8.  Mechanisms of hyperhomocysteinemia induced skeletal muscle myopathy after ischemia in the CBS-/+ mouse model.

Authors:  Sudhakar Veeranki; Suresh C Tyagi
Journal:  Int J Mol Sci       Date:  2015-01-06       Impact factor: 5.923

Review 9.  Modulation of hydrogen sulfide by vascular hypoxia.

Authors:  Jessica M Osmond; Nancy L Kanagy
Journal:  Hypoxia (Auckl)       Date:  2014-08-25

10.  Exercise mitigates the effects of hyperhomocysteinemia on adverse muscle remodeling.

Authors:  Lee J Winchester; Sudhakar Veeranki; Sathnur Pushpakumar; Suresh C Tyagi
Journal:  Physiol Rep       Date:  2018-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.